| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CLO &Secretary | Chief Legal Officer & | Chief Legal Officer & +1 more
3 companies
Reardon Andrew serves as a CLO &Secretary at LGND and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 0 buys and 67 sells. Those positions are worth an estimated $21.0M at current prices.
Historically, Reardon Andrew's trades have earned a below-average insider score of 26/100 across 7 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -63.6%.
The biggest single holding is LGNYZ (~$10.9M) as CLO &Secretary. The recent filings there lean toward selling, a net 25,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | LGNYZ Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $304.07 | $1,520,345.87 | -13.6% | - | - | |
| Sep 3, 2026 | LGNYZ Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sell | 5,000 | $286.09 | $1,430,434.39 | -12.0% | - | - | |
| Aug 3, 2026 | LGNYZ Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $288.99 | $1,444,950.90 | -10.7% | - | - | |
| Jul 1, 2026 | LGNYZ Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $313.28 | $1,566,376.99 | -10.7% | - | - | |
| Jun 1, 2026 | LGNYZ Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $227.06 | $1,135,315.57 | -10.8% | - | - | |
| May 1, 2026 | LGND Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $231.31 | $1,156,555.60 | -10.8% | - | - | |
| Apr 1, 2026 | LGND Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $201.24 | $1,006,224.10 | -10.8% | - | - | |
| Mar 4, 2026 | LGND Ligand Pharmaceuticals Incorporated | CLO &Secretary | Sale+OE | 5,000 | $206.35 | $1,031,770.27 | -11.9% | - | - | |
| Jun 23, 2025 | LGND Ligand Pharmaceuticals Inc | CLO &Secretary | Sell | 500 | $114.08 | $57,042.15 | -1.5% | +48.5% | +143.0% | |
| Jun 10, 2025 | LGND Ligand Pharmaceuticals Inc | CLO &Secretary | Sell | 500 | $114.54 | $57,270.70 | -1.5% | +46.2% | +118.9% |